Aerovate Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Aerovate Therapeutics, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Clinical-stage rare disease biotech with challenged lead program but substantial funding and recent strategic merger to sustain operations. AV-101 failed in treatment of PAH as of June 2024, creating significant clinical and financial headwinds. However, the company has raised $203M, providing runway for clinical development, and the merger with.
What is Aerovate Therapeutics, Inc.'s industry? Aerovate Therapeutics, Inc. (aerovatetx.com) operates in Orphan Drugs. AskCyborg classifies Aerovate Therapeutics, Inc. under Orphan Drugs in its company registry.
Aerovate Therapeutics is a clinical-stage biopharmaceutical company developing drugs for rare cardiopulmonary disease, with primary focus on AV-101, a dry powder inhaled formulation of imatinib for pulmonary arterial ...
Cyborg Score thesis
Clinical-stage rare disease biotech with challenged lead program but substantial funding and recent strategic merger to sustain...
Read the full analyst-debate transcript →Get the Latest Aerovate Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAerovate Therapeutics, Inc. Overview
Pro stress-test →Aerovate Therapeutics is a clinical-stage biopharmaceutical company developing drugs for rare cardiopulmonary disease, with primary focus on AV-101, a dry powder inhaled formulation of imatinib for pulmonary arterial hypertension (PAH). AV-101 delivers medicine directly to diseased lung tissues while reducing systemic adverse side effects. The company operates in a highly specialized niche within rare disease therapeutics.
Strategic Profile
Pro stress-test →Aerovate underwent a reverse merger with Jade Biosciences on April 28, 2025, which expanded its operational capacity and platform. The company operates in the pulmonology sector, competing against established players like Gossamer Bio and Corsair Pharma. With a clinical-stage asset and recent merger integration, Aerovate is positioned to advance its lead program through ongoing development.
Competitive Landscape
Pro stress-test →Top competitors include Gossamer Bio, Actelion, and Corsair Pharma. These companies also focus on rare cardiopulmonary and pulmonary hypertension therapeutics. Aerovate's differentiation lies in its inhaled dry powder approach to imatinib delivery, though clinical efficacy has been questioned by recent trial results.
Industry Context
Aerovate Therapeutics, Inc. operates in Orphan Drugs.
Key facts
Founded: 2018 · Headquarters: Waltham, US · Employees: 4 · Revenue: N/A · Market cap: $483.59M